The primary clinical application of Neratinib lies in its role as an extended adjuvant therapy for adult patients who have previously undergone Trastuzumab-based treatment for early-stage breast cancer characterized by HER2-positive status. The gene discussed is ERBB2; the disease is breast cancer.